INTRODUCTION

54
Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), 55 is a chronic disorder of the gastrointestinal tract. Considerable variation in the epidemiology of 56 IBD has been observed around the world, with the highest incidence rates and prevalence in 57 North America and Europe; notably, over 1.4 million people in the United States suffer from 58 IBD (32, 41) . Although the etiology of IBD is not fully understood, it is thought to involve a 59 multi-factorial interaction of inheritable components, environmental stress, microbial insults and 60 autoimmune events (24, 28) . Currently a number of experimental IBD models have been Although none of these models precisely mimic the human disorders, they have proven to be 64 useful for a more complete understanding of the mechanistic basis of this disease, identifying 65 new targets for therapeutic intervention, and testing novel therapeutic agents (30, 46, 51) .
66
Peroxisome proliferator-activated receptor α (PPARα) is a nuclear hormone receptor which 67 serves as a xenobiotic and lipid sensor to regulate energy combustion, hepatic steatosis, agonist, decreased susceptibility to acute colitis in mice, which is correlated with decreased 72 production of IFNγ, IL-1β, and TNFα (4) . In hyperlipidemic patients, fenofibrate treatment 73 decreased the plasma concentrations of the inflammatory cytokine interleukin-6 (48). However, 74 in contrast with these results, increased plasma TNFα levels were observed in fenofibrate or 14643-treated endotoxemic mice, possibly due to modulation of TNFα by PPARα. Thus, this 76 study suggested that the systemic hypolipidemic effect of PPARα ligands in vivo might be 77 proinflammatory (21). In addition, mitochondrial dysfunction caused by fibrates was revealed 78 based on studies of membrane potential, mitochondrial swelling, and assays of the respiratory 79 chain in isolated mitochondria by respirometry (8, 35) . In the clinic, increased colitis was 80 reported to the FDA by mostly elderly patients taking fenofibrate (15). Since fibrates are being 81 prescribed for a significant population of elderly patients, it is therefore important to determine 82 the impact of these drugs on the host response to acute inflammation and further investigate to 50% A at 3 min, to 1% A at 8 min, held until 15min, then returning to initial conditions over 1 161 min, and held for an additional 2 min for column equilibration. Flow rate was 0.4 ml/min.
162
Column temperature was maintained at 50C. Waters Xevo TQ was operated in MRM mode.
163
The following instrument conditions were used: Capillary 2.2kV, source temp 150C, desolvation increased whereas LPC 18:1 and LPC 18:2 decreased in the serum of mice with colitis (10).
251
These trends were further confirmed in colons of the colitis mice in this study (data not shown). were significantly increased as compared to control diet-treated colitis mice, confirming that
270
PPARα is activated by fenofibrate in liver ( Figure 7A ) and colon ( Figure 7B ) (42, 54). In colon, colitis. Indeed, current evidence supports a role for sphingolipids including SM and CER in 299 modulating inflammation (3, 16) . In this study, increased SM and CER levels were observed in 300 both serum and colon of DSS treated mice. It was reported that the activity of a specific intestinal 301 alkaline sphingomyelinase, which also hydrolyzes SM, was reduced in the rat colitis model as 302 well as in ulcerative colitis and colon cancer patients (3, 47). Higher SM concentrations were 303 also detected in ileum from patients suffering from Crohn's disease (7). These findings of down- though the specific mechanism for CER accumulation herein still awaits further study.
326
In colon, expression of Cpt1 mRNA was up-regulated after fenofibrate treatment. 
